Cannabis-focused biopharmaceutical company Avicanna Inc. AVCN AVCNF (FSE:0NN) announced on Monday the launch of re+PLAY sports recovery-based CBD brand through a partnership with Harrington Wellness, founded by NBA veteran Al Harrington.
The brand’s initial product offerings include:
- Muscle Rub – a water-based emulsion consisting of 500 mg of pure CBD with complementary natural active ingredients including menthol, camphor and the terpene beta-caryophyllene.
- Total Body Cream - a water-based emulsion combining 250 mg of pure CBD with complementary natural active ingredients including menthol, beta-caryophyllene and eucalyptus essential oil for an immediate cooling sensation with a light scent.
- Foot + Ankle Cream - a fast-absorbing, lightly scented cream combines 500 mg of pure CBD with soothing colloidal oatmeal as well as antimicrobial tea tree and spearmint essential oils to provide a cool but gentle sensation on the feet.
CBD-based topicals utilize Avicanna’s proprietary and evidence-based deep tissue technology for cannabinoid delivery and have been curated with the support of Harrington Wellness’ deep understanding of the needs of professional athletes.
“We are thrilled to be expanding our wellness product offerings within the Canadian marketplace and to be introducing the first sports-focused THC-Free line of functional products,” Aras Azadian, Avicanna’s CEO said. “This line has been curated through this world-class partnership with the Harrington Wellness team and been in development since 2019.”
The products are now available across adult use channels in Alberta and are expected to launch in early 2022 in Ontario and other provinces.
re+PLAY will also be available through medical channels in partnership with Medical Cannabis by Shoppers nationwide in early January.
More recent news from Avicanna:
Avicanna To Bring Its Cannabinoid-Based Drugs To Argentina Via 'Established' Pharma Partner
Avicanna Expands Medical Cannabis Brand RHO Phyto Into Caribbean Region With Export To Barbados
AVCNF Price Action
Avicanna’s shares traded 6.52% lower at $0.5865 per share at the market close on Friday.
Photo: Courtesy of Avicanna Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.